0000000000101528

AUTHOR

Giovanni Tuccari

showing 5 related works from this author

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct

HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily.

2013

According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of his…

OncologyCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastric adenocarcinoma; HER2 status; Sicily; TrastuzumabHER2 gastric carcinomaSettore MED/08 - Anatomia PatologicaTrastuzumabInternal medicinemedicineStage (cooking)skin and connective tissue diseasesneoplasmsSicilyChemotherapyHER2 status; Sicily; gastric adenocarcinoma; trastuzumabHER2 statusbusiness.industryCancerArticlesmedicine.diseaseMolecular medicinetrastuzumabOncologyCohortTubular AdenocarcinomaImmunohistochemistrygastric adenocarcinomabusinessmedicine.drug
researchProduct

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation …

2012

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin-fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. …

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryCancerRetrospective cohort studyArticlesProgesterone Receptor StatusSettore MED/08 - Anatomia Patologicamedicine.diseaseClinical trialBreast carcinoma immunohistochemistry HER2medicine.anatomical_structureOncologyTrastuzumabInternal medicineCohortsmall size breast cancer screening campaign staging immunohistochemistrymedicineBreast carcinomabusinessLymph nodemedicine.drug
researchProduct

Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investiga…

2014

Antonio Ieni,1 Valeria Barresi,1 Rosario Caltabiano,2 Anna Maria Cascone,3 Rachele Del Sordo,4 Daniela Cabibi,5 Pio Zeppa,3 Salvatore Lanzafame,2 Angelo Sidoni,4 Vito Franco,5 Giovanni Tuccari1 1Department of Human Pathology Gaetano Barresi, Section of Anatomic Pathology, University of Messina, Messina, 2Department GF Ingrassia, Section of Anatomic Pathology, University of Catania, Catania, 3Department of Medicine and Surgery, University of Salerno, Salerno, 4Institute of Pathologic Anatomy and Histology, Division of Cancer Research, University of Perugia, Perugia, 5Department of Human Pathology, Section of Anatomic Pathology, University of Palermo, Palermo, Italy Background: Human epiderma…

Pathologymedicine.medical_specialtysynchronous lymph nodeslcsh:RC254-282OncoTargets and TherapyBreast cancer Human epidermal growth factor receptor 2 Metastases Prognosis Synchronous lymph nodesText miningBreast cancerbreast cancermedicinebreast cancer; human epidermal growth factor receptor 2; metastases; prognosis; synchronous lymph nodesPharmacology (medical)metastasesskin and connective tissue diseasesneoplasmsLymph nodeHuman Epidermal Growth Factor Receptor 2Original Researchbusiness.industryhuman epidermal growth factor receptor 2; breast cancer; synchronous lymph nodes; metastases; prognosishuman epidermal growth factor receptor 2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemedicine.anatomical_structureOncologysynchronous lymph nodemetastaseprognosisbusinessBreast carcinoma
researchProduct

Role of trastuzumab in infracentimetric HER2-positive breast cancer: The southern Italy experience.

2014

e11512 Background: HER2 positive (HER2+) disease is relatively uncommon in early infracentimetric breast cancer (BC) accounting for approximately 10% of cases. Trastuzumab (T) based-adjuvant therap...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryDiseasemedicine.diseaseBreast cancerOncologyTrastuzumabInternal medicineHER2 Positive Breast Cancermedicineskin and connective tissue diseasesbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct